Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Prescient Therapeutics Limited ( (AU:PTX) ) just unveiled an announcement.
Prescient Therapeutics has announced the opening of a Share Purchase Plan (SPP) to raise up to $7 million, allowing eligible shareholders to purchase new shares at a discounted price. The funds raised will be used to advance the clinical development of PTX-100, which is currently progressing through Phase 2 trials and has shown promising efficacy and safety in treating T cell lymphomas.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited is a clinical stage oncology company listed on the ASX, focusing on developing personalized medicine approaches to cancer. The company specializes in targeted and cellular therapies, with its leading product PTX-100, a first-in-class compound that inhibits cancer growth enzymes, currently in clinical development.
Average Trading Volume: 903,701
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$37.04M
For an in-depth examination of PTX stock, go to TipRanks’ Overview page.